Spyre Therapeutics Hits 4-Year High on Trial Win, Then Sells $300 Million in Stock
NEW YORK, April 14 —
Spyre Therapeutics' lead drug SPY001 cleared every Phase 2 endpoint for ulcerative colitis, and the company celebrated by diluting shareholders with a $300mn offering.
- SPY001 met all Phase 2 endpoints in ulcerative colitis, with analysts comparing its efficacy to Takeda's existing treatment
- Deutsche Bank raised its price target to $88 from $55, Mizuho to $84 from $53, Wedbush to $80 from $65. All maintain buy-equivalent ratings
- Spyre launched a $300mn public stock offering at the same time, locking in the elevated share price
What Actually Happened
Phase 2 data is the inflection point for biotech stocks. Before it, you're betting on science. After it, you're betting on execution. SPY001 just crossed that line. The drug hit all its endpoints in ulcerative colitis, a condition affecting roughly 1 million Americans. Analysts immediately started repricing the asset.
Three banks moved at once. Deutsche Bank's target jump from $55 to $88 is a 60% increase. Mizuho went from $53 to $84. Wedbush from $65 to $80. Three separate desks raising targets on the same day means one thing: the data beat expectations. Shares hit a 4-year high near $63.63.
The Catch
The $300mn offering. Spyre's management watched the stock spike and immediately filed to sell new shares. That's a sensible move for a pre-revenue biotech that needs to fund a Phase 3 trial. It's also dilution. And it tells you how management views the current price: high enough to sell into.
Phase 2 to Phase 3 is where biotech bets get tested. The ulcerative colitis market already has entrenched players. A Phase 3 trial will be larger, longer, and more expensive. That $300mn isn't a war chest — it's the entry fee. The forward P/E of negative 21.2x is a reminder: there are no earnings here, just a drug candidate and a strong dataset.
Bottom Line
This is a real result. Phase 2 data that rivals an existing marketed drug in a large GI indication is exactly what early biotech investors look for. But the stock already reflects much of that success, and the company just confirmed it by selling $300mn in shares into the rally. The next milestone: Phase 3 trial design and timeline. If Spyre announces a fast, efficient pivotal study, the analyst targets have room to rise. If the trial design looks bloated or the timeline slips, this becomes a "sell the news" story — with more shares outstanding.
For a full financial breakdown on Spyre Therapeutics, generate a free SYRE report on Basis Report.
Basis Report does not hold positions in securities discussed. This is not investment advice.